ERBB2 and non-small cell lung carcinoma: In a phase 3 randomized study (DESTINY-Lung04), T-DXd is being tested against the standard of care (investigator’s choice of cisplatin/carboplatin + pembrolizumab + pemetrexed) in patients with advanced/metastatic NSCLC harboring a HER2 exon 19 or 20 mutations [51].